Neurology
Found 19 results
Filters: Keyword is Treatment Outcome  [Clear All Filters]
2021
Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D et al..  2021.  Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.. Adv Ther. 38(7):3724-3742.
2019
Merkler AE, Chen ML, Parikh NS, Murthy SB, Yaghi S, Goyal P, Okin PM, Karas MG, Navi BB, Iadecola C et al..  2019.  Association Between Heart Transplantation and Subsequent Risk of Stroke Among Patients With Heart Failure.. Stroke. 50(3):583-587.
Kamel H, Longstreth WT, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinzer C, Dillon C, Ewing I, Spilker JA et al..  2019.  The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods.. Int J Stroke. 14(2):207-214.
Reynolds AS, Chen ML, Merkler AE, Chatterjee A, Diaz I, Navi BB, Kamel H.  2019.  Effect of A Randomized trial of Unruptured Brain Arteriovenous Malformation on Interventional Treatment Rates for Unruptured Arteriovenous Malformations.. Cerebrovasc Dis. 47(5-6):299-302.
Gerges MM, Godil SS, Rumalla K, Liechty B, Pisapia DJ, Magge RS, Schwartz TH.  2019.  Genomic profile of a primary squamous cell carcinoma arising from malignant transformation of a pineal epidermoid cyst.. Acta Neurochir (Wien). 161(9):1829-1834.
Mandava P, Murthy SB, Shah N, Samson Y, Kimmel M, Kent TA.  2019.  Pooled analysis suggests benefit of catheter-based hematoma removal for intracerebral hemorrhage.. Neurology. 92(15):e1688-e1697.
Saber H, Navi BB, Grotta JC, Kamel H, Bambhroliya A, Vahidy FS, Chen PRoc, Blackburn S, Savitz SI, McCullough L et al..  2019.  Real-World Treatment Trends in Endovascular Stroke Therapy.. Stroke. 50(3):683-689.
Horlick E, Kavinsky CJ, Amin Z, Boudoulas KDean, Carroll JD, Hijazi ZM, Leifer D, Lutsep HL, Rhodes JF, Tobis JM.  2019.  SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologist. Catheter Cardiovasc Interv. 93(5):859-874.
Chatterjee A, Merkler AE, Murthy SB, Burch JE, Chen ML, Gialdini G, Kamel H, Ballman KV, Navi BB.  2019.  Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer.. J Stroke Cerebrovasc Dis. 28(8):2255-2261.
2018
Omran SSalehi, Boddu SReddy, Gusdon AM, Kummer B, Baradaran H, Patel P, Diaz I, Navi BB, Gupta A, Kamel H et al..  2018.  Angiographic Blush after Mechanical Thrombectomy is Associated with Hemorrhagic Transformation of Ischemic Stroke.. J Stroke Cerebrovasc Dis. 27(11):3124-3130.
Noch EK, Ramakrishna R, Magge R.  2018.  Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance.. World Neurosurg. 116:505-517.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.. Mult Scler. 24(4):540-542.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Merkler AE, Gialdini G, Kamel H.  2018.  Response by Merkler et al to Letter Regarding Article, "Safety Outcomes After Percutaneous Transcatheter Closure of Patent Foramen Ovale".. Stroke. 49(1):e17.
2017
Vo ML, Chin RL, Miranda C, Latov N.  2017.  Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.. Muscle Nerve. 56(4):732-736.
Murthy SB, Merkler AE, Omran SSalehi, Gialdini G, Gusdon A, Hartley B, Roh D, Mangat HS, Iadecola C, Navi BB et al..  2017.  Outcomes after intracerebral hemorrhage from arteriovenous malformations.. Neurology. 88(20):1882-1888.
Murthy SB, Awad I, Harnof S, Aldrich F, Harrigan M, Jallo J, Caron J-L, Huang J, Camarata P, Lara LRivera et al..  2017.  Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial.. Neurology. 89(4):355-362.
2016
Merkler AE, Parikh NS, Chaudhry S, Chait A, Allen NC, Navi BB, Kamel H.  2016.  Hospital revisit rate after a diagnosis of conversion disorder.. J Neurol Neurosurg Psychiatry. 87(4):363-6.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.